ScoreComparison
Why is Repare Therapeutics, Inc. ?
1
The company has declared Negative results for the last 4 consecutive quarters
- NET SALES(HY) At USD 0.25 MM has Grown at -99.53%
- NET PROFIT(HY) At USD -40.14 MM has Grown at -85.72%
- OPERATING CASH FLOW(Y) Lowest at USD -103.33 MM
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -30.49%, its profits have fallen by -169.8%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -2.29% over the previous quarter and currently hold 28.38% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -30.49% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Repare Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Repare Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Repare Therapeutics, Inc.
-30.53%
-0.53
87.94%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.56%
EBIT Growth (5y)
-199.25%
EBIT to Interest (avg)
-80.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.32
Tax Ratio
1.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.04%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.50
EV to EBIT
0.46
EV to EBITDA
0.47
EV to Capital Employed
-26.69
EV to Sales
-55.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-98.52%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING PROFIT(Q)
Highest at USD -18.95 MM
PRE-TAX PROFIT(Q)
Highest at USD -13.04 MM
NET PROFIT(Q)
Highest at USD -13.36 MM
EPS(Q)
Highest at USD -0.39
-25What is not working for the Company
NET SALES(HY)
At USD 0.25 MM has Grown at -99.53%
NET PROFIT(HY)
At USD -40.14 MM has Grown at -85.72%
OPERATING CASH FLOW(Y)
Lowest at USD -103.33 MM
ROCE(HY)
Lowest at -69.96%
DEBT-EQUITY RATIO
(HY)
Highest at -98.56 %
RAW MATERIAL COST(Y)
Grown by 689.31% (YoY
CASH AND EQV(HY)
Lowest at USD 233.7 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.02 times
Here's what is working for Repare Therapeutics, Inc.
Operating Profit
Highest at USD -18.95 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -13.04 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -13.36 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD -13.04 MM has Grown at 56.99%
over average net sales of the previous four periods of USD -30.32 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -13.36 MM has Grown at 56.64%
over average net sales of the previous four periods of USD -30.81 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.39
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for Repare Therapeutics, Inc.
Net Sales
At USD 0.25 MM has Grown at -99.53%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -103.33 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -98.56 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at USD 233.7 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 0.02 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 689.31% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
